Bladder Cancer Outcomes Favor Enfortumab–Pembrolizumab
Perioperative enfortumab vedotin plus pembrolizumab improved survival and complete response rates versus cisplatin chemotherapy in resectable muscle-invasive bladder cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.